{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:38:54Z","timestamp":1792024734167,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,16]]},"DOI":"10.7759\/cureus.52377","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:44:26Z","timestamp":1705419866000},"source":"Crossref","is-referenced-by-count":8,"title":["Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib"],"prefix":"10.7759","author":[{"given":"Zahidul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Toker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha M","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Campton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1132574","article-title":"Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review","volume":"10","author":"Yu Y","year":"2023","unstructured":"Yu Y, Ding X, Guo F, Ze K, Sun X, Li X. Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review. Front Med (Lausanne). 2023, 10:1132574. 10.3389\/fmed.2023.1132574","journal-title":"Front Med (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5070\/D3205022692","article-title":"Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa","volume":"20","author":"Scheinfeld N","year":"2014","unstructured":"Scheinfeld N. Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa. Dermatol Online J. 2014, 20:22692. 10.5070\/D3205022692","journal-title":"Dermatol Online J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi A","year":"2022","unstructured":"Alavi A, Hamzavi I, Brown K, et al.. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022, 186:803-13. 10.1111\/bjd.20969","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2020.1770948","article-title":"JAK inhibitors for the treatment of rheumatoid arthritis","volume":"43","author":"Morinobu A","year":"2020","unstructured":"Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. 2020, 43:148-55. 10.1080\/25785826.2020.1770948","journal-title":"Immunol Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier JM","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al.. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018, 2:23. 10.1186\/s41927-018-0031-x","journal-title":"BMC Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study","volume":"87","author":"Kozera E","year":"2022","unstructured":"Kozera E, Flora A, Frew JW. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study. J Am Acad Dermatol. 2022, 87:1440-2. 10.1016\/j.jaad.2022.07.047","journal-title":"J Am Acad Dermatol"},{"key":"ref7","unstructured":"FDA approves first oral treatment for moderately to severely active CR. (2023). Accessed. September 13, 2023: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-oral-treatment-moderately-severely-active-crohns...."},{"key":"ref8","article-title":"Upadacitinib","author":"Padda IS","year":"2023","unstructured":"Padda IS, Bhatt Rajat, Parmar Mayur. Upadacitinib. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1642441","article-title":"Approach to treatment of refractory dissecting cellulitis of the scalp: a systematic review","volume":"32","author":"Thomas J","year":"2021","unstructured":"Thomas J, Aguh C. Approach to treatment of refractory dissecting cellulitis of the scalp: a systematic review. J Dermatolog Treat. 2021, 32:144-9. 10.1080\/09546634.2019.1642441","journal-title":"J Dermatolog Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.3969","article-title":"Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series","volume":"31","author":"Frechet L","year":"2021","unstructured":"Frechet L, Puzenat E, Charollais R, et al.. Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series. Eur J Dermatol. 2021, 31:81-5. 10.1684\/ejd.2021.3969","journal-title":"Eur J Dermatol"},{"key":"ref11","article-title":"Dissecting cellulitis of the scalp responding to intravenous tumor necrosis factor-alpha antagonist","volume":"5","author":"Wollina U","year":"2012","unstructured":"Wollina U, Gemmeke A, Koch A. Dissecting cellulitis of the scalp responding to intravenous tumor necrosis factor-alpha antagonist. J Clin Aesthet Dermatol. 2012, 5:36-9.","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222394-improvement-of-recalcitrant-dissecting-cellulitis-of-the-scalp-after-a-trial-of-upadacitinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:47Z","timestamp":1707509567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222394-improvement-of-recalcitrant-dissecting-cellulitis-of-the-scalp-after-a-trial-of-upadacitinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.52377","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}